

THE ROLE OF AMINO ACIDS AND THEIR METABOLITES IN SUPPORTING MUSCLE HEALTH IN AGING AND ILLNESS

LEUCINE AND β -HYDROXY- β -METHYLBUTYRATE (HMB)

What is Leucine?

- Leucine is one of nine essential amino acids, a branched chain amino acid, that must be consumed in the diet.
- Leucine is important for muscle protein synthesis and many metabolic functions.¹



What is Beta-hydroxy-beta-methylbutyrate (HMB)?

- HMB is a metabolite derived from the amino acid leucine.
- HMB works with protein and amino acids to support muscle protein synthesis while reducing protein breakdown that can lead to muscle loss.²⁻⁴

Importance of muscle and dietary protein intake with aging and illness:

Research shows that nutrition strategies that include dietary protein, amino acids, and amino acid metabolites can improve muscle mass, strength, and function.⁵⁻⁸

DID YOU KNOW?

Most studied dose of CaHMB is

3 g/day

Only about

0.5-5%
of dietary leucine is converted to HMB^{2,9}

Individuals need at least

60 grams of leucine to get 3 grams of HMB

60 g of leucine is equivalent to eating

110 eggs

THE ROLE OF AMINO ACIDS AND THEIR METABOLITES IN SUPPORTING MUSCLE HEALTH IN AGING AND ILLNESS

LEUCINE AND β -HYDROXY- β -METHYLBUTYRATE (HMB)

DO LEUCINE AND HMB HAVE THE SAME EFFECTS ON PROTEIN ANABOLISM AND MUSCLE MASS?

- **Leucine** supplementation increases muscle protein synthesis and may be useful to address the age-related decline in muscle mass in elderly individuals. The effect on muscle strength shows mixed results, and there are limited data on physical performance.¹⁰
- **HMB** has been shown to increase muscle mass in healthy aging adults, preserve muscle mass during extended bed rest, and enhance recovery during exercise rehabilitation.¹¹⁻¹³
- **HMB** has a longer half-lifetime in the blood than that of leucine, which may favour the use of HMB above leucine to achieve protein anabolism.¹⁴
- **A systematic review** and meta-analysis of 15 randomized controlled trials reporting outcomes in adults with clinical conditions characterized by loss of skeletal muscle mass and weakness revealed:¹⁵
 - » HMB, or supplements containing HMB, have been shown to increase skeletal muscle mass.
 - » HMB supported improvements in muscle strength.

WHAT DO ESPEN GUIDELINES RECOMMEND?

2.2 In malnourished polymorbid medical inpatients or those at high risk of malnutrition, nutrient-specific ONS should be administered, when they may maintain muscle mass, reduce mortality, or improve quality of life.^{16*}

7.1 In polymorbid medical inpatients with pressure ulcers, specific amino-acids (arginine and glutamine) and β -hydroxy- β -methylbutyrate (β HMB) can be added to oral/enteral feeds to accelerate the healing of pressure ulcers.¹⁶

9.3 In polymorbid medical inpatients at high risk of malnutrition or with established malnutrition aged 65 and older, continued nutritional support post-hospital discharge with either ONS or individualized nutritional intervention shall be considered to lower mortality.^{16*}

***Supporting evidence for these guidelines referenced the NOURISH study:**

Supplementation with ONS (20 g high protein, 1.5 g CaHMB, 350 kcal, 160 IU vitamin D, and other essential micronutrients) twice a day reduced the risk of mortality by 50% through 90 days post-hospital discharge in malnourished, cardiopulmonary patients 65 years or older compared to patients receiving a placebo and standard of care.¹⁷

VISIT ANHI.ORG FOR A DIGITAL COPY OF THIS INFOGRAPHIC.

HMB = β -hydroxy- β -methylbutyrate

References:
1. Norton LE and Layman DK. *J Nutr* 2006;136(2):533S-37S. | 2. Nissen SL, Abumrad NN. *J Nutr Biochem* 1997;8:300-11. | 3. Wilkinson DJ, et al. *J Physiol* 2013;591(11):2911-23. | 4. Eley HL, et al. *Am J Physiol Endocrinol Metab* 2008;295:E1409-16.
5. Wolfe RR. *Br J Nutr* 2012;108:S88-S93. | 6. Bauer J, et al. *J Am Med Dir Assoc* 2013;14:542-59. | 7. Deutz NE, et al. *Clin Nutr* 2014;33:929-36. | 8. Argiles JM, et al. *J Am Med Dir Assoc* 2016;7(9):789-96. | 9. Walker D, et al. *J Chromat B* 2017;1040:233-8.
10. Martínez-Arnau FM, et al. *Nutrients* 2019;11(10):2504. | 11. Vukovich MD, et al. *J Nutr* 2001;131(7):2049-52. | 12. Stout JR, et al. *Exp Gerontol* 2013;48(11):1303-10. | 13. Deutz NEP, et al. *Clin Nutr* 2013;32(5):704-12.
14. Engelen MPKJ, Deutz NEP. *Curr Opin Clin Nutr Metab Care* 2018;21(3):207-13. | 15. Bear DM, et al. *Am J Clin Nutr* 2019;109(4):1119-32. | 16. Gomes F, et al. *Clin Nutr* 2018;37:336-53. | 17. Deutz NEP, et al., *Clin Nutr* 2016;35(1):18-26.